Circulating myostatin as a biomarker of muscle mass and strength in individuals with cancer or obesity

Abstract

Background & AimsOur study aims to determine whether myostatin (MSTN) is associated with muscle mass and strength in individuals with cancer or obesity, as well as with cancer cachexia (CC) or sarcopenic obesity (SO). MethodsThe ACTICA study included individuals with CC (n=70) or without CC (NC, n=73). The MYDIASECRET study included individuals with obesity evaluated before (T0) and 3 months (T3) after bariatric surgery (n=62). Body composition was assessed using bioelectrical impedance analysis (BIA). Skeletal muscle mass (SMM) and appendicular SMM (ASMM) were calculated from Janssen’s and Sergi’s equations, respectively, and expressed as indexes (SMMI and ASMMI). Handgrip strength (HGS) was assessed using a Jamar hand-held dynamometer. MSTN plasma levels were measured using ELISA. Spearman’s coefficient was used to correlate MSTN with muscle mass and strength. Receiver operating characteristic (ROC) curve analysis was performed to identify an optimal MSTN cutoff level for the prediction of CC or SO. ResultsIn the ACTICA study, muscle mass and strength were lower in CC individuals than in NC individuals (SMMI: 8.0 kg/m2vs 9.0 kg/m2, p=0.004; ASMMI: 6.2 kg/m2vs 7.2 kg/m2, p<0.001; HGS: 28 kg vs 38 kg, p<0.001). MSTN was also lower in CC individuals than in NC individuals (1434 pg/mL vs 2149 pg/mL, p<0.001). Muscle mass and strength were positively correlated with MSTN (SMMI: R=0.500, p<0.001; ASMMI: R=0.479, p<0.001; HGS: R=0.495, p<0.001). ROC curve analysis showed a MSTN cutoff level of 1548 pg/mL (AUC 0.684, sensitivity 57%, specificity 75%, p<0.001) for the prediction of CC. In the MYDIASECRET study, muscle mass and strength were reduced at T3 (SMMI: -8%, p<0.001; ASMMI: -12%, p<0.001; HGS: -6%, p=0.005). MSTN was also reduced at T3 (1773 pg/mL vs 2582 pg/mL, p<0.001). Muscle mass and strength were positively correlated with MSTN at T0 and T3 (SMMI-T0: R=0.388, p=0.002; SMMI-T3: R=0.435, p<0.001; HGS-T0: R=0.337, p=0.007; HGS-T3: R=0.313, p=0.013). ROC curve analysis showed a MSTN cutoff level of 4225 pg/mL (AUC 0.835, sensitivity 98%, specificity 100%, p=0.014) for the prediction of SO at T3. ConclusionsMSTN is positively correlated with muscle mass and strength in individuals with cancer or obesity, suggesting its potential use as a biomarker of muscle mass and strength. The ROC curve analysis suggests the potential use of MSTN as a screening tool for CC and SO.